anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This disclosure generally relates to implantable devices for controlled drug delivery without a pre-defined orifice. Many current drug delivery devices rely on at least one orifice to permit the release of drugs from the devices. While an orifice may allow for some control over drug release, orifice-containing devices may potentially expel an undesirable amount of drug when compressed after deployment. For example, an orifice-containing device deployed in the bladder may be compressed during bladder contraction, thereby forcing an undesirable amount of drug out of the orifice. The compression of orifice-containing devices may release toxic amounts of drugs, especially when the drugs are potent, such as anti-cancer drugs. This problem can be mitigated, to some degree, by decreasing the size of the orifice of a particular device. As the size of the orifice decreases, however, the likelihood that the orifice will clog after deployment increases. A clogged orifice is undesirable because it often leads to less reproducible drug release, or it may prevent drug release entirely. Aside from possible mechanical difficulties, adding an orifice to a device increases the device’s complexity and cost of the components and/or manufacturing. This is especially true when an orifice of a small and precise diameter, such as one ranging from 75 to 300 microns, is needed to ensure that the device is capable of releasing drug at a desired rate. In other cases, a drug delivery device may not have a release orifice and release of drug is controlled by diffusion from a matrix material and/or through a wall. Such configurations which rely on diffusion, however, may limit the drug release kinetics that can be achieved and/or may limit the range of suitable materials of construction to ones that lack the desired biocompatibility, stability, sterilizability, and mechanical properties, including manufacturability, wall thickness, flexibility, etc. There exists a need for a drug delivery device that overcomes one or more of these disadvantages. An orifice-free drug delivery device is provided. In an embodiment, the device includes a body having at least one water-permeable wall bounding a reservoir defined within the body. A drug formulation is disposed within the reservoir. The body has an elastic portion and at least one restraining plug closing off an opening of the body. The opening is in fluid communication with the reservoir, and the restraining plug contacts the elastic portion of the body and controls release of the drug from the device by the transient formation of one or more microchannels between the elastic portion of the body and the at least one restraining plug. The elastic portion may define an opening having an inner diameter, which is exceeded by the outer diameter of the restraining plug by at least 3 %.
The study will be of a double blind, randomized, two period crossover design. Two treatments, digoxin in combination with YM150, and digoxin in combination with placebo, will be evaluated. Each subject will receive both treatments in random order. Placebo will be used to maintain the blind. Males and females will be equally divided over the treatment orders.

Subjects will be dosed with digoxin and either YM150 or placebo for 8 days to reach steady state. In the second period the subjects will receive digoxin and the alternate treatment. There will be a washout period of at least 10 days between the consecutive treatments. In both study periods the subjects will be admitted the day prior to study drug administration (Day 0). The subjects will be discharged on Day 10. Approximately one week after the last discharge, the subjects will return to the unit for a post study visit.
STUDY RATIONAL The education sector represents a reliable system for malaria control. Intermittent preventive therapy in schoolchildren (IPTsc) is likely the most feasible and appropriate chemoprevention in stable and endemic areas because schoolchildren are usually asymptomatic to malaria infection and are consequently untreated in practice. Therefore, if proven effective, IPTsc would be of direct benefit for the schoolchild, contribute to malaria control at school, and facilitate community-wide the implementation of other control interventions i.e. vector control, Intermittent preventive therapy in infants (IPTi), and prompt diagnosis and treatment (PDT). Nevertheless, evidence about use of IPTsc is not yet substantiated as only two clinical studies have so far been performed on IPTsc in hyper endemic areas. Further clinical trials are warranted in other settings. Through a randomised controlled trial (RCT) we will assess the efficacy and safety, of two IPT regimens versus controls in school children of the DRCongo.

STUDY DRUGS Favourable drugs for use as IPT should balance long half-life against efficacy, safety, tolerability and potentiality for cross-resistance selection.(16) Use of long-acting drugs would result in fewer intake and higher treatment compliance. Sulfadoxine-pyrimethamine is an established used product in the indication of IPT in pregnancy. The drug has further proven safety and tolerability in children in clinical trials. SP is slowly eliminated and allows 60 days antimalaria protection for fully sensitive P. falciparum. Other long-acting drugs available are mefloquine, amodiaquine, and piperaquine. However, due safety concern mefloquine might not be optimal for IPT. Amodiaquine is not suitable for IPT due to its 3 days treatment regimen that may be a concern regarding compliance. Piperaquine has been extensively used for mass prophylaxis and treatment since 1978 in China and other malaria endemic countries of Asia.(20) Piperaquine has a long half-live and points as good IPT candidate in endemic country with SP resistance. For this study sulfadoxine-pyrimethamine combined with piperaquine (SP-PQ) plus will be used. SP and SP-PQ will be given at 4 months intervals in line with the long half-lives (around 20 days) in paediatric patients and for higher treatment compliance,
PODOCON-25® IS TO BE APPLIED ONLY BY A PHYSICIAN. IT IS NOT TO BE DISPENSED TO THE PATIENT. SHAKE WELL. Thoroughly cleanse affected area. Use supplied applicator to apply Podocon-25® sparingly to lesion. Avoid contact with healthy tissue. Allow to dry thoroughly. Only intact (no bleeding) lesions should be treated. As podophyllin is a powerful caustic and severe irritant, it is recommended the first application of Podocon-25® be left in contact for only a short time (30-40 minutes) to determine patient’s sensitivity. To avoid systemic absorption, time of contact should be minimum time necessary to produce the desired result (1 to 4 hours, depending on condition of lesion and of patient), the physician developing his/her own experience and technique. Large areas or numerous warts should not be treated at once.

After treatment time has elapsed, remove dried Podocon-25® thoroughly with alcohol or soap and water.
The disclosed systems and methods provide an efficient solution to manage the entries of versioned libraries. A method includes receiving a request to modify an entry corresponding to a numerically-versioned library or a related master. The method includes obtaining a first snapshot record for the entry corresponding to the library or the master. The method includes receiving user changes to data of the entry. The method also includes generating a second snapshot record for the entry. The second snapshot record capturing the user changes and having an assigned second plurality of version identification values. The method further includes updating the first plurality of version identification values of the first snapshot record based on assigned values of the second plurality of version identification values of the second snapshot record. The first and second plurality of version identification values indicating that the first snapshot record precedes the second snapshot record.
The overarching objective of this project is to test whether diagnostic assessments informed by data on molecular cerebral changes can lead to improved health outcomes of an epidemiologically major segment of the geriatric patient population - people experiencing changes in their cognitive skills relative to their prior level of cerebral functioning. In the present proposal, we specifically aim to measure how knowledge of molecular cerebral information 1) influences the therapeutic management of patients being evaluated for symptoms of cognitive decline, and 2) impacts upon long-term health outcomes, particularly for patients having findings on positron emission tomography (PET) scans consistent with presence of Alzheimer's disease (AD)- like changes in their brains. Patients suffering from documentable decline of cognitive function will undergo baseline neuropsychologic testing, and neuroimaging with MRI and PET. Reports of PET scans will be sealed at the time of interpretation, and then randomized with respect to whether they are released to the patients' managing physicians at the time of interpretation, or two years after the time that scanning is performed. All treatment decisions will be made by the managing physicians and their patients. Cognitive abilities, functional status, and other clinical and social history parameters will be assessed every six months. Our central hypothesis is that among the group of patients whose PET scan results are conveyed to their physicians at the time of scanning, cognitive and functional abilities will be maintained at a higher level during the two years following PET. Beyond addressing the specific aims noted above and further described below, a valuable feature of this project will be the collection of a rich source of data that can be used to address many questions beyond its major focus (e.g., diagnostic value of volumetric MRI data used instead of, or in conjunction with, PET data in the Medicare beneficiary population; incremental value of applying statistically parameterizing and/or quantifying software tools to PET data). The protocol has been designed to conform to all standards specified by the Centers for Medicare and Medicaid Services (CMS) for Coverage with Evidence Development (CED), generally, and with all requirements for a CED study responsive to CMS Decision Memo CAG-00431N, specifically.
PCT No. PCT/FI93/00409 Sec. 371 Date Jul. 31, 1995 Sec. 102(e) Date Jul. 31, 1995 PCT Filed Oct. 8, 1993 PCT Pub. No. WO94/08567 PCT Pub. Date Apr. 28, 1994The object of the invention is a process for the preparation of drug pellets, which method comprises the stages according to which: a drug containing powder is granulated in a rotor type granulator, by exerting a centrifugal force on the powder in the rotor and bringing it, at the periphery of the rotor or adjacent thereto, in contact with a granulating liquid fed separately into the rotor and converted to a mist therein, to which granulating liquid an anti-adhesion agent in an amount of 0.001-5% of the weight of the granulating liquid has been added; the granulate is extruded; and the extrudate obtained is spheronized to pellets which are dried and optionally coated.
The role of inflammation in disease promotion is significant, yet the precise association between a newly identified inflammatory biomarker and insulin resistance (IR) and mortality remains uncertain. We aim to explore the potential correlation between systemic immune-inflammation index (SII) and these factors. We used data from 2011 to 2016 of National Health and Nutrition Examination Survey, and multivariate logistic regression and restricted cubic spline were employed. Subgroup and interaction analysis were conducted to recognize the consistency of the results. The association between SII and mortality was described by survival analysis. 6734 participants were enrolled, of whom 49.3% (3318) exhibited IR and 7.02% experienced mortality. Multivariate logistic regression revealed that individuals in the highest quartile (Q4) of SII had a significantly increased risk of IR compared to those in the lowest quartile (Q1). We then identified a linear association between SII and IR with an inflection point of 407, but may be influenced by gender. Similarly, compared to Q1, people whose SII at Q4 showed a higher all-cause and cardiovascular mortality. It showed a significant association between SII and both all-cause and cardiovascular mortality, but the results need to be interpreted with caution.
BACKGROUND: Neural Tube Defects (NTDs) are congenital malformations of the central nervous system resulting from the incomplete closure of the neural tube during early embryonic development. Neuroinflammation refers to the inflammatory response in the nervous system, typically resulting from damage to neural tissue. Immune-related processes have been identified in NTDs, however, the detailed relationship and underlying mechanisms between neuroinflammation and NTDs remain largely unclear. In this study, we utilized integrated multi-omics analysis to explore the role of neuroinflammation in NTDs and identify potential prenatal diagnostic markers using a murine model.
METHODS: Nine public datasets from Gene Expression Omnibus (GEO) and ArrayExpress were mined using integrated multi-omics analysis to characterize the molecular landscape associated with neuroinflammation in NTDs. Special attention was given to the involvement of macrophages in neuroinflammation within amniotic fluid, as well as the dynamics of macrophage polarization and their interactions with neural cells at single-cell resolution. We also used qPCR assay to validate the key TFs and candidate prenatal diagnostic genes identified through the integrated analysis in a retinoic acid-induced NTDs mouse model.
RESULTS: Our analysis indicated that neuroinflammation is a critical pathological feature of NTDs, regulated both transcriptionally and epigenetically within central nervous system tissues. Key alterations in gene expression and pathways highlighted the crucial role of STATs molecules in the JAK-STAT signaling pathway in regulating NTDs-associated neuroinflammation. Furthermore, single-cell resolution analysis revealed significant polarization of macrophages and their interaction with neural cells in amniotic fluid, underscoring their central role in mediating neuroinflammation associated with NTDs. Finally, we identified a set of six potential prenatal diagnostic genes, including FABP7, CRMP1, SCG3, SLC16A10, RNASE6 and RNASE1, which were subsequently validated in a murine NTDs model, indicating their promise as prospective markers for prenatal diagnosis of NTDs.
CONCLUSIONS: Our study emphasizes the pivotal role of neuroinflammation in the progression of NTDs and underlines the potential of specific inflammatory and neural markers as novel prenatal diagnostic tools. These findings provide important clues for further understanding the underlying mechanisms between neuroinflammation and NTDs, and offer valuable insights for the future development of prenatal diagnostics.
This pilot study entails a two-phase process. During Phase I, 15 former YMHP participants (intervention decliners and those who only completed one session) will participate in focus groups to advise us on the feasibility and pragmatic specifications of an HIV prevention intervention received via the IM (instant messaging) function of Facebook. Focus group transcripts will be examined to isolate key recommendations for modifying the intervention's structure and procedures. Focus groups will be reconvened for additional feedback on the modified intervention, followed by further adjustment. During Phase II, 40 high-risk YMSM (ages 18-29 and Facebook users) will be enrolled in a pilot of the modified intervention. The intervention will span 4 weeks and contain 8 bi-weekly 30 minute Motivational Interviewing (MI) chat-window sessions consisting of a sequential progression of intervention approaches tailored to each participant's readiness to change their drug use and high risk sexual behavior. Data from Phase II will include pre-post intervention behavioral risk assessments, as well as individual interviews with all 40 intervention participants for a qualitative evaluation regarding the feasibility and acceptability of the intervention's structure, and process. Findings from these interviews (and counselor focus group) will inform the fine-tuning of the intervention in preparation for a subsequent randomized control trial (RCT).
Complexes of antithrombin (III) (A3) and heparin or heparinoids are prepd. in the form of concentrates by (i) treating human plasma or an A3-contg. plasma fraction with heparin(oid) (ii) adsorbing the resulting complex on an anion exchanger (iii) eluting adsorbate with a salt soln. (iv) separating the complex in the eluate from salts and unwanted proteins and (v) freeze drying the prod.. - Pref. the adsorbate is washed before elution. The eluate is treated with a precipitant, e.g. (NH4)2SO4, in an amt. sufficient to ppte. the complex, which is then redissolved and the soln. is heat-inactivated, treated with sufficient precipitant to remove unwanted proteins without precipitating the complex, and then freeze dried.
Subjects will be treated monthly for 6 months by Pain Medicine Specialist (PMS) per standard protocol. The PCP will not be involved in the treatment.
In the control group, participants will be asked to complete written questionnaires in the outpatient clinic before surgery and at 1, 3, and 6 months after surgery. Based on the questionnaires, a clinician will provide a solution at an outpatient clinic. However, the Wecare® platform was not provided. .
PURPOSE: A functional health food is provided such that fermented soybean powder is added to green tea to obtain a fermented green tea extract. CONSTITUTION: A manufacturing method of anti-diabetic fermented food comprises a step of adding fermented soybean powder to green tea and fermenting the mixed green tea at a temperature of 20-30>=. The fermented soybean powder is 0.1-5 parts by weight based on the total by weight. The fermented soybean powder is pre-fermented at a temperature of 75-90>=. The fermented soybean powder is post-fermented at a temperature of 75-90>=. The fermentation is carried out with a relative humidity of 55-65 for 30-45 days. Diabetes is type 2 diabetes. [Reference numerals] (AA) Blood sugar value(mg/dL); (BB) Control group; (CC) Positive control group; (DD) Green tea; (EE) Green tea fermented product; (FF) Period(days);
Pancreatic cancer is a kind of cancer with poor prognosis. Nowadays, recommended treatment for late-stage or recurrent pancreatic cancer patients are fluorouracil based chemotherapy (such as FOLFIRINOX) and gemcitabine based chemotherapy. When these two chemo regimes are failed, however, there is no alternative options. With the improvement of immune therapy, anti-PD-1 antibody has became a promising anti-cancer drug. While it showed limited efficacy in pancreatic cancer. Stereotactic Body Radiotherapy (SBRT) has been a new method to locally treat metastatic cancer. And previous studies showed that SBRT may enhance the efficacy of immunotherapy. So this study is amed to evaluate the safety and efficacy of the combination of SBRT and anti-PD-1 antibody in late-stage or recurrent pancreatic caner who failed in second-line chemotherapy.
We propose to conduct a first test of the effect of the dopamine D3 receptor antagonist, GSK598809, on smoking behavior when treatment is started immediately following the quit date. To do this, we propose to conduct a 10-week, double-blind, placebo-controlled, proof of mechanism study in 90 adult smokers. Participants will complete baseline evaluations. They will receive manualized cognitive behavioral therapy, beginning prior to the quit date, and will set a quit date for the day before their week 2 study visit. They will be given short acting NRT (gum or lozenge) to use on their quit date. They will be asked to arrive for the week 2 visit with 18-24 hours abstinence and an expired air CO ≤ 10ppm. Those who do so will be randomly assigned to receive double blind GSK598809 or identical placebo for six weeks. Participants will begin double blind GSK598809 or placebo, both in conjunction with prn NRT up to 8 mg per day for two weeks. Participants will then continue double blind GSK598809 or placebo in the absence of NRT for 4 more weeks. At the end of this period (week 8 of the study), participants will then be followed 2 weeks after discontinuation of double blind treatment to complete the 10 weeks of the study.
Methods, systems, devices and apparatuses for generating a high-quality MRI image from under-sampled or corrupted data The image reconstruction system includes a memory. The memory is configured to store multiple samples of biological, physiological, neurological or anatomical data that has missing or corrupted k-space data and a deep learning model or neural network. The image reconstruction system includes a processor coupled to the memory. The processor is configured to obtain the multiple samples. The processor is configured to determine the missing or corrupted k-space data using the multiple samples and the deep learning model or neural network. The processor is configured to reconstruct an MRI image using the determined missing or corrupted k-space data and the multiple samples.
PURPOSE:To provide an external drug for skin, containing a pharmacologically active substance and an oleaginous base containing a gas selected from carbon dioxide, hydrogen sulfide and radon. CONSTITUTION:The objective external drug for skin contains (A) an oleaginous base (e.g. vegetable oil such as olive oil, almond oil, etc., animal oil such as lanolin, beeswax, beef tallow, etc., synthetic oil such as liquid paraffin, fatty acic such as hexanoic acid, or natural or synthetic fatty acid triglyceride, etc.) containing at least one kind of gas selected from carbon dioxide, hydrogen sulfide and radon, and (B) a pharmacologically active substance (e.g. analgesic anti-inflammatory agent such as ethyl aminobenzoate, antipruritic such as ichthammol, disinfection sterilizer such as phenol, astringent such as zinc oxide, emolelient such as refined sulfur, antimycotic agent such as chrysarobin, etc.). EFFECT:Sufficient effect can be attained even at a low concentration of the pharmacologically active sustance, and the side effect of the drug can be mitigated.
PURPOSE: To obtain a compsn. which contains a fatty acid of specified chain length or its monoglyceride and is effective to deactivate envelop virus and to induce cell death. CONSTITUTION: This compsn. contains an effective amt. of pharmaceutical component and an inactive pharmaceutical carrier and has an antimicrobial effect. The pharmaceutical component consists of one or more kinds of compds. selected from 4 to 14C, preferably 7 to 12C fatty acids, monoglycerides of these fatty acids, 14 to 22C, preferably 16 to 18C unsatd. monofatty acids or unsatd. polyfatty acids or monoglycerides of these unsatd. monofatty acids or unsatd. polyfatty acids. Further, a lipase inhibitor, preferably a bile salt comprising sodium of lithium taurocholate is preferably incorporated into this compsn. As for the pharmaceutical component, caprylic acid, capric acid, lauric acid, and especially monocapric acid and 1-O-octyl-SN-glycerol are preferable. The obtd. compsn. is effective to prevent and remove bacteria, fungi and envelope virus.
Potato starch and magnesium stearate will constitute the comparator arm (Placebo). Participants will take two capsules per day (one closed capsule to swallow and one open capsule mixed with maple syrup) for 10 days and one closed capsule per day to swallow for the following 15 days. They will stop the treatment if they are admitted to the hospital. The treatment will last a maximum of 25 days.